Skip to main content

Review Weighs Treatments for Genitourinary Symptoms of Menopause

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 10, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine.

Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations.

The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia, the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms.

"Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

Abstract/Full Text (subscription or payment may be required)

Evidence Map (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Air Pollution May Worsen Bone Health in Postmenopausal Women

FRIDAY, May 16, 2025 -- Exposure to air pollution may worsen bone loss in postmenopausal women, according to a study published online April 24 in the Journal of Bone and...

More Research Needed to Prepare People With Mental Illness for Menopause

THURSDAY, May 15, 2025 -- Few studies examine how people living with a mental illness may be best prepared for the menopause transition, considering both menopause symptoms and...

Hormone Therapy Tied to Worse Bladder Health in Postmenopausal Women

TUESDAY, May 6, 2025 -- Hormone therapy use is linked to worse bladder health in postmenopausal women, according to a study published online April 29 in Menopause. Camille...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.